Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Placebo-Controlled Proof of Concept Study of ANB020 in Severe Eosinophilic Asthma
2017-000647-40Phase 2Unknown
- Sponsor
- AnaptysBio, Inc.
- Start
- Apr 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in eosinophilic asthma (EA) comparing ANB020 with Placebo (2 arms). Primary endpoint: Treatment-related adverse events. Status: unknown.
02
Drugs
etokimab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on 2017-000647-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000647-40.